Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progression Clear all
Completed Phase 3 Interventional

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

NCT00053599
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 27, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Withdrawn Phase 1 Interventional

A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

NCT02661659
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM)
Interventions
Multipeptide vaccine S-588210
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 27, 2026, 9:54 PM EDT
Not listed No phase listed Observational

Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology

NCT01316159
View directory record Official record
Conditions
Coronary Atherosclerosis, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Endothelial Shear Stress, Arterial Remodeling
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 27, 2026, 9:54 PM EDT
Completed No phase listed Observational

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury

NCT05316727
View directory record Official record
Conditions
Acute Lung Injury, Pulmonary Injury, Electronic Cigarette Use, Electronic Cigarette Related Lung Injury
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 27, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

NCT00031473
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Virazole (Ribavirin) Inhalation Solution
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

NCT00185042
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Pactimibe, CS-505
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 27, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

Cryoablation+Ipilimumab+Nivolumab in Melanoma

NCT05779423
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Ipilimumab, Nivolumab, Cryoablation
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Completed No phase listed Observational

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

NCT00435214
View directory record Official record
Conditions
Cervical Neoplasia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years to 100 Years · Female only
Enrollment
131,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 27, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional

Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer

NCT04131634
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Stereotactic Ablative Radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 27, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

NCT01840592
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib, Doxorubicin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Not listed Phase 4 Interventional

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 27, 2026, 9:54 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Not listed Phase 2 Interventional

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

NCT04398524
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx
Interventions
ISA101b
Drug
Lead sponsor
ISA Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 27, 2026, 9:54 PM EDT
Not listed No phase listed Observational

A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

NCT04743323
View directory record Official record
Conditions
Pancreatitis, Acute, Alcohol Drinking, Health Behavior
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 27, 2026, 9:54 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

NCT04349280
View directory record Official record
Conditions
Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Lake Success, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 27, 2026, 9:54 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469
View directory record Official record
Conditions
Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions
[F-18]Flornaptitril
Drug
Lead sponsor
CereMark Pharma, LLC
Industry
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 27, 2026, 9:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Not listed No phase listed Observational

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

NCT05214105
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Diseases, Chronic
Interventions
Biospecimen/DNA collection and analysis
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 27, 2026, 9:54 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

NCT03689595
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Samples of blood (2-4 tablespoons) from 4 tubes will be collected -Analysis will be performed on the blood to test for multiple myeloma precursor conditions.
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Recruiting Not applicable Interventional

Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression

NCT06636838
View directory record Official record
Conditions
Infertility, Infertility (IVF Patients), Infertility Assisted Reproductive Technology, Ovulation Ind
Interventions
Spanish-Speaking Provider
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 27, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Results available

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

NCT04034251
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
Interventions
Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 9:54 PM EDT
Active, not recruiting Not applicable Interventional

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

NCT05786456
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8
Interventions
Discussion, Informational Intervention, Media Intervention, Questionnaire Administration, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 27, 2026, 9:54 PM EDT